Table 4 Impact on the mean management cost of a lung cancer patient of a ±30% variation in first-line (L1) chemotherapy costs and second- or third-line (L2) chemotherapy costs and a 30% fall in palliative care (PC) costs
From: Economics of the clinical management of lung cancer in France: an analysis using a Markov model
Mean cost (US$) | L1 chemotherapy costs (%) | L2 chemotherapy costs (%) | PC costs (%) | |
|---|---|---|---|---|
Variation | ±30 | ±30 | −30 | |
Local Op NSCLC | 25 050 | ±3.5 | ±1.1 | −4 |
Local Nop NSCLC | 24 443 | ±2.9 | ±2.7 | −13.6 |
LA-Ad NSCLC | 27 794 | ±6.5 | ±3.1 | −2.9 |
LA-Nad NSCLC | 24 579 | ±8.4 | ±4.9 | −6.1 |
Diffuse NSCLC | 20 691 | ±10.6 | ±2.7 | −6.9 |
Local SCLC | 31 833 | ±8.5 | ±2.7 | −4.2 |
Diffuse SCLC | 20 184 | ±11.7 | ±2.3 | −4.2 |
